Physician profile
Michael A Workman
NPI 1184731267
$1,228.16
in general payments reported to CMS, 2019-2025
13 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $83.25 · 2021: $11.69 · 2022: $99.45 · 2023: $123 · 2024: $550 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.01 | 2021-2025 | Vraylar |
| Pfizer INC. | $155.71 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $99.45 | 2022 | |
| Novo Nordisk INC | $99.10 | 2023-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $85.92 | 2020-2024 | Zepbound |
| Depuy Synthes Sales INC. | $81.42 | 2024 | Embotrap |
| Glaxosmithkline, LLC. | $51.36 | 2020-2024 | Arexvy, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $24.42 | 2024 | Vaxneuvance, Capvaxive |
| Phathom Pharmaceuticals, INC. | $24.16 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $23.87 | 2025 | Trintellix |
| Astellas Pharma US INC | $22.03 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $19.02 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $13.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.